A5088482428- Synthesis and biological activity
- Sphingolipid Metabolism and Signaling
- Melanoma and MAPK Pathways
- Click Chemistry and Applications
- Protein Kinase Regulation and GTPase Signaling
- Enzyme function and inhibition
- Endoplasmic Reticulum Stress and Disease
- Protein Tyrosine Phosphatases
- Erythrocyte Function and Pathophysiology
- Cancer Cells and Metastasis
- Lymphatic System and Diseases
- Lipid Membrane Structure and Behavior
- Computational Drug Discovery Methods
- Angiogenesis and VEGF in Cancer
- Psoriasis: Treatment and Pathogenesis
- Silymarin and Mushroom Poisoning
Centre de Recherche en Cancérologie de Toulouse
2018-2023
Université Toulouse III - Paul Sabatier
2018-2021
Inserm
2018-2021
Centre National de la Recherche Scientifique
2021
Université de Toulouse
2018
Abstract BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation. However, resistance BRAFi is inevitable. Here, we identified sphingosine 1-phosphate (S1P) receptors as regulators of BRAFV600E-mutant cell-autonomous BRAFi. Moreover, our results reveal a distinct sphingolipid profile, that is, tendency for increased very long-chain ceramide species, in plasma who achieve response therapy compared progressive disease. Treatment resulted strong decrease...
Triple-negative breast cancer (TNBC) is notoriously aggressive with a high metastatic potential, and targeted therapies are lacking. Using transcriptomic histologic analysis of TNBC samples, we found that expression thrombospondin-1 (TSP1), potent endogenous inhibitor angiogenesis an activator latent transforming growth factor beta (TGF-β), associated (i) gene signatures epithelial-mesenchymal transition TGF-β signaling, (ii) metastasis (iii) reduced survival in patients. In contrast, tumors...
<p>Supplementary Figure S2 shows the plasma SL levels in patients responding or not to BRAFi</p>
<p>Supplementary Figure S3 shows the effect of SKI-I on cell death in BRAFi-sensitive and -resistant melanoma cells</p>
<p>Supplementary Figure S1 shows the effects of PLX on S1PR expression and cell death in BRAFi-sensitive -resistant melanoma cells</p>
<p>Supplementary Figure S4 shows that MITF expression is associated to S1PR1 in PLX-treated melanoma cells</p>
<p>Legends to the supplemental figures</p>
<div>Abstract<p>BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation. However, resistance BRAFi is inevitable. Here, we identified sphingosine 1-phosphate (S1P) receptors as regulators of BRAF<sup>V600E</sup>-mutant cell-autonomous BRAFi. Moreover, our results reveal a distinct sphingolipid profile, that is, tendency for increased very long-chain ceramide species, in plasma who achieve response therapy compared progressive...
<p>Supplementary Figure S1 shows the effects of PLX on S1PR expression and cell death in BRAFi-sensitive -resistant melanoma cells</p>
<p>Supplementary Figure S4 shows that MITF expression is associated to S1PR1 in PLX-treated melanoma cells</p>
<p>Supplementary Figure S3 shows the effect of SKI-I on cell death in BRAFi-sensitive and -resistant melanoma cells</p>
<p>Legends to the supplemental figures</p>
<p>Supplementary Figure S2 shows the plasma SL levels in patients responding or not to BRAFi</p>
<div>Abstract<p>BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation. However, resistance BRAFi is inevitable. Here, we identified sphingosine 1-phosphate (S1P) receptors as regulators of BRAF<sup>V600E</sup>-mutant cell-autonomous BRAFi. Moreover, our results reveal a distinct sphingolipid profile, that is, tendency for increased very long-chain ceramide species, in plasma who achieve response therapy compared progressive...